Mutations in the F404 locus of the ESR1 gene have been identified as a specific acquired resistance mechanism conferring resistance to the selective estrogen receptor degrader (SERD) fulvestrant in breast cancer cells. This evidence concerns the gene ESR1 and breast carcinoma.